Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women
Open Access
- 1 January 2010
- journal article
- review article
- Published by Hindawi Limited in Journal of Osteoporosis
- Vol. 2010, 1-5
Abstract
Osteoclasts are specialized cells that initiate the process of bone resorption, which has two phases, dissolution of the mineral component and degradation of the organic matrix, in which cathepsin K plays a key role. Cathepsin K inhibitors, which block the activity of cathepsin on bone resorption lacunae, may be a new therapeutic option in osteoporosis. Odanacatib is a nonpeptidic biaryl inhibitor of cathepsin K. Two studies have evaluated the efficacy and safety of odanacatib, a phase I study to determine the dose and a phase II study of safety and efficacy. Due to the long half-life of odanacatib and the similar effects of different doses on bone remodeling markers, a weekly dosage was chosen for the phase II trail, with the best results being obtained with a dose of 50 mg. At 36 months, increases in bone mineral density similar to those produced by other powerful antiresorptive drugs (zoledronate and denosumab) were observed but there were differences in the behaviour of bone remodeling markers. Data on fractures from the phase III trial currently in development are required to confirm these possible advantages.Keywords
This publication has 22 references indexed in Scilit:
- Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone densityJournal of Bone and Mineral Research, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Cathepsin K inhibitors for osteoporosis and potential off-target effectsExpert Opinion on Investigational Drugs, 2009
- Giant Osteoclast Formation and Long-Term Oral Bisphosphonate TherapyNew England Journal of Medicine, 2009
- Anti-resorptive therapies for osteoporosisSeminars in Cell & Developmental Biology, 2008
- Biochemical properties and regulation of cathepsin K activityBiochimie, 2008
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Osteonecrosis of the jaw—a potential adverse effect of bisphosphonate treatmentNature Clinical Practice Endocrinology & Metabolism, 2006
- The role of T lymphocytes in bone metabolismImmunological Reviews, 2005
- Minireview: The OPG/RANKL/RANK SystemEndocrinology, 2001